ES2071306T3 - El uso de tensioactivos fluorados solubles para la preparacion de formulaciones aerosoles dosificadas. - Google Patents

El uso de tensioactivos fluorados solubles para la preparacion de formulaciones aerosoles dosificadas.

Info

Publication number
ES2071306T3
ES2071306T3 ES91907436T ES91907436T ES2071306T3 ES 2071306 T3 ES2071306 T3 ES 2071306T3 ES 91907436 T ES91907436 T ES 91907436T ES 91907436 T ES91907436 T ES 91907436T ES 2071306 T3 ES2071306 T3 ES 2071306T3
Authority
ES
Spain
Prior art keywords
preparation
spray formulations
fluorinated surfactants
soluble fluorinated
dosage spray
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91907436T
Other languages
English (en)
Inventor
Robert K Schultz
Stephen N Quessy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Application granted granted Critical
Publication of ES2071306T3 publication Critical patent/ES2071306T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

SE DESCRIBEN FORMULACIONES EN AEROSOL DE SUSPENSIONES FARMACEUTICAS EN LAS QUE SE UTILIZA/N UNO O MAS ACIDOS CARBOXILICOS PERFLUORADOS O SUS ESTERES COMO AGENTES DISPERSANTES ACTIVOS EN LA SUPERFICIE Y 1,1,12
ES91907436T 1990-03-23 1991-03-22 El uso de tensioactivos fluorados solubles para la preparacion de formulaciones aerosoles dosificadas. Expired - Lifetime ES2071306T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49833390A 1990-03-23 1990-03-23

Publications (1)

Publication Number Publication Date
ES2071306T3 true ES2071306T3 (es) 1995-06-16

Family

ID=23980625

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91907436T Expired - Lifetime ES2071306T3 (es) 1990-03-23 1991-03-22 El uso de tensioactivos fluorados solubles para la preparacion de formulaciones aerosoles dosificadas.

Country Status (7)

Country Link
EP (3) EP0965335B1 (es)
JP (1) JPH05505824A (es)
AU (1) AU654813B2 (es)
CA (1) CA2077354A1 (es)
DE (3) DE69109284T2 (es)
ES (1) ES2071306T3 (es)
WO (1) WO1991014422A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
ES2151476T3 (es) * 1990-06-28 2001-01-01 Glaxo Wellcome Inc Formulaciones de farmacos en aerosol.
US5785952A (en) * 1990-11-09 1998-07-28 Glaxo Group Limited Aerosol medicament formulation having a surface coating of surfactant
CZ271393A3 (en) * 1991-06-10 1994-07-13 Schering Corp Aerosol preparations without chlorofluorinated hydrocarbons
US5474759A (en) * 1991-06-10 1995-12-12 Schering Corporation Non-chlorofluorocarbon aerosol formulations
DE4123663A1 (de) * 1991-07-17 1993-01-21 Schwabe Willmar Gmbh & Co Aerosol-zubereitung und verwendung eines treibmittels dafuer
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
DK0616524T3 (da) 1991-12-12 1999-06-21 Glaxo Group Ltd Lægemidler
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
WO1993011745A1 (en) * 1991-12-12 1993-06-24 Glaxo Group Limited Medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US5376359A (en) * 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
MX9304585A (es) 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
WO1994021229A1 (en) * 1993-03-17 1994-09-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
AU679510B2 (en) * 1993-03-17 1997-07-03 Minnesota Mining And Manufacturing Company Aerosol formulation containing a diol-diacid derived dispersing aid
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
DK0735884T3 (da) * 1993-12-20 2000-10-09 Minnesota Mining & Mfg Flunisolid-aerosolformuleringer
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
GB9419536D0 (en) * 1994-09-28 1994-11-16 Glaxo Inc Medicaments
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5874469A (en) * 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
GB9805938D0 (en) 1998-03-19 1998-05-13 Glaxo Group Ltd Valve for aerosol container
US6264923B1 (en) 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US6451287B1 (en) 2000-05-26 2002-09-17 Smithkline Beecham Corporation Fluorinated copolymer surfactants and use thereof in aerosol compositions
WO2002024623A2 (en) 2000-09-22 2002-03-28 Glaxo Group Limited Novel alkanoic acid derivatives
KR100881258B1 (ko) 2000-12-22 2009-02-05 글락소 그룹 리미티드 살메테롤 지나포에이트를 위한 정량식 흡입기
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
RU2004103075A (ru) * 2001-08-03 2005-04-20 Глаксо Груп Лимитед (GB) Соединения сурфактанты и их применение
GB0125127D0 (en) * 2001-10-19 2001-12-12 Glaxo Group Ltd Compounds
GB0128148D0 (en) 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
AU2003205860A1 (en) 2002-02-13 2003-09-04 Glaxo Group Limited Carboxylic acid compounds for use as surfactants
GB0205327D0 (en) 2002-03-06 2002-04-17 Glaxo Group Ltd compounds
WO2004110460A1 (en) 2003-06-13 2004-12-23 Altana Pharma Ag Formoterol and ciclesonide combination
WO2005003075A1 (ja) * 2003-07-02 2005-01-13 Daikin Industries, Ltd. フルオロアルキルカルボン酸誘導体、含フッ素重合体の製造方法及び含フッ素重合体水性分散液
US8198354B2 (en) 2003-08-11 2012-06-12 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
WO2005023330A2 (en) 2003-08-29 2005-03-17 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
AU2004271744B2 (en) 2003-09-16 2010-07-29 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases
JP2007533387A (ja) 2004-04-21 2007-11-22 イノベータ バイオメド リミテッド 吸入器
KR20090129998A (ko) 2007-02-11 2009-12-17 맵 파마슈티컬스, 인코포레이티드 부작용 프로파일을 최소화하면서 편두통의 빠른 완화를 가능하게 하는 ｄｈｅ의 치료적 투여 방법
EP2384337A1 (en) 2009-01-05 2011-11-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
RU2012156256A (ru) 2010-06-04 2014-07-20 ТРИФОЙЛИУМ АпС Факторы трилистника (tff) для лечения хронических заболеваний легких
SG188401A1 (en) 2010-09-09 2013-04-30 Trifoilium Aps Airway administration of angiogenesis inhibitors
JP2014519519A (ja) 2011-06-15 2014-08-14 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規３，４，４ａ，１０ｂ−テトラヒドロ−１Ｈ−チオピラノ［４，３−ｃ］イソキノリン化合物
PE20140648A1 (es) 2011-06-17 2014-05-30 Takeda Gmbh Novedosos derivados de ftalazinona-pirrolopirimidinacarboxamida
WO2018069210A1 (en) 2016-10-10 2018-04-19 Takeda Gmbh Tetrahydrofuro[3,4-c]isoquinolines as inhibitors of pde4

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3250808A (en) * 1963-10-31 1966-05-10 Du Pont Fluorocarbon ethers derived from hexafluoropropylene epoxide
US4044126A (en) * 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
JPS5331582A (en) * 1976-09-04 1978-03-24 Daikin Ind Ltd Aerosol composition
US4352789A (en) * 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
GB8900267D0 (en) * 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol

Also Published As

Publication number Publication date
EP0636362A3 (en) 1995-12-27
DE69109284D1 (de) 1995-06-01
AU654813B2 (en) 1994-11-24
JPH05505824A (ja) 1993-08-26
DE69131867D1 (de) 2000-01-27
EP0526481B1 (en) 1995-04-26
DE69133314D1 (de) 2003-10-23
EP0965335A1 (en) 1999-12-22
DE69109284T2 (de) 1995-08-24
WO1991014422A1 (en) 1991-10-03
EP0636362A2 (en) 1995-02-01
EP0965335B1 (en) 2003-09-17
CA2077354A1 (en) 1991-09-24
AU7668691A (en) 1991-10-21
EP0636362B1 (en) 1999-12-22
DE69131867T2 (de) 2000-05-18
EP0526481A1 (en) 1993-02-10

Similar Documents

Publication Publication Date Title
ES2071306T3 (es) El uso de tensioactivos fluorados solubles para la preparacion de formulaciones aerosoles dosificadas.
ES2118835T3 (es) 2-etil-1h-imidazo(4,5-c)quinolin-4-aminas antiviricas.
ES2080739T3 (es) Nitro-compuestos insecticidamente activos.
ES2176355T3 (es) Formulaciones de aerosol de peptidos y proteinas.
ITFI930247A1 (it) Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche.
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
DE60033684D1 (de) Phenylalaninderivate
BR9202675A (pt) Processo e aparelho para distribuir um material polente cosmeticamente ativo para o corpo,composicao eletrostaticamente pulverizavel,e.uso de uma pulverizacao eletrostatica
MX9205046A (es) 1h-imidazo-(4,5-c)quinolin-4-aminas 1-substituidas
ES2081936T3 (es) Composiciones anfoteras y formas polimericas de alfa-hidroxiacidos, y su uso terapeutico.
MX9300014A (es) Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion.
MX9100198A (es) Formulacion para detergentes altamente activas
DK0556256T3 (da) Aerosolmedikamenter
PT98105A (pt) Processo para a preparacao de formulacoes em aerossol contendo como propulsor 1,1,1,2-tetrafluoroetano
ES2175413T3 (es) Formulaciones de aerosol.
DK0582239T3 (da) Farmaceutisk og/eller kosmetisk formulering
BR9709845B1 (pt) preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina.
CO5001019A1 (es) Composicion emulsionable para la represion de insectos, que se deriva del tipo de fenilpirazoles sustituidos en posi- cion 1, y no favorecen la formacion de cristales
ES2101230T3 (es) Nuevos derivados de sustancias anti-inflamatorias, analgesicas y/o antipireticas no estereoideas, su uso y formulaciones farmaceuticas que las contienen.
ES2051754T3 (es) Uso de derivados cetonicos en el tratamiento de la depresion.
ES2093782T3 (es) Piridazindionas y su uso en el tratamiento de trastornos neurologicos.
ES2134237T3 (es) Composiciones farmaceuticas que contienen acido ursodesoxicolico.
ES2087279T3 (es) El uso de giberelinas para el tratamiento de la prostatitis y la psoriasis.
ES2052484T1 (es) N-(5-tioxo-l-prolil)-l-cisteina, sus derivados, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
IT1240683B (it) Composizione farmaceutica contenente egf

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 526481

Country of ref document: ES